GlassScriptPhysician profile
Muhammad Shabbir
NPI 1285879338
$2,522.64
in general payments reported to CMS, 2019-2025
33 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $182 · 2021: $379 · 2022: $244 · 2023: $364 · 2024: $602 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.83 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $317.37 | 2019-2023 | Spravato, Xarelto |
| Novo Nordisk INC | $250.51 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $246.69 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $239.43 | 2019-2024 | |
| Lilly USA, LLC | $131.09 | 2019-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $125.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $114.30 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $101.05 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $98.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.46 | 2022-2024 | Jardiance, Tradjenta |
| Amgen INC. | $78.62 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $77.92 | 2020-2025 | Mavyret |
| Hologic Sales and Service, LLC | $73.05 | 2020-2024 | Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $59.66 | 2023-2025 | |
| Abbott Laboratories | $49.16 | 2024-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $48.66 | 2019-2020 | |
| Exact Sciences Corporation | $48.00 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.86 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $35.67 | 2021 | |
| Abiomed | $26.11 | 2025 | |
| Merck Sharp & Dohme LLC | $25.54 | 2020-2023 | Vaxneuvance, Vaqta, Gardasil 9 |
| Dexcom, INC. | $24.95 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $23.59 | 2024 | |
| Corcept Therapeutics | $23.24 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $21.67 | 2025 | Recorlev |
| Genentech USA, INC. | $21.11 | 2019 | |
| Emd Serono, INC. | $20.96 | 2024 | |
| Mylan Specialty L.P. | $20.23 | 2020 | |
| Gilead Sciences, INC. | $19.43 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $19.04 | 2023 | Elyxyb |
| Eisai INC. | $16.75 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shabbir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.